Chronic Lymphocytic Leukemia (CLL)

Oncology
21
Pipeline Programs
11
Companies
26
Clinical Trials
9 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
1
10
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
873%
Cell Therapy
218%
Monoclonal Antibody
19%
+ 12 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
5 programs
3
1
ObinutuzumabPhase 3Monoclonal Antibody2 trials
AcalabrutinibPhase 2Small Molecule1 trial
VenetoclaxPhase 21 trial
VenetoclaxPhase 21 trial
VenetoclaxN/A1 trial
Active Trials
NCT03873857Completed71Est. Sep 2022
NCT07024706Not Yet Recruiting80Est. May 2029
NCT05105841Completed20Est. Oct 2025
+3 more trials
M&
Merck & Co.RAHWAY, NJ
1 program
1
DinaciclibPhase 3Small Molecule1 trial
Active Trials
NCT01580228Completed44Est. Dec 2014
GS
Gilead SciencesFOSTER CITY, CA
3 programs
2
1
IdelalisibPhase 2Small Molecule1 trial
IdelalisibPhase 1Small Molecule1 trial
IdelalisibPhase 1Small Molecule
Active Trials
NCT02538614Terminated2Est. Jul 2017
NCT01203930Terminated105Est. Jun 2016
Nurix Therapeutics
Nurix TherapeuticsBRISBANE, CA
3 programs
2
1
NX-5948Phase 21 trial
NX-2127Phase 11 trial
NX-5948Phase 11 trial
Active Trials
NCT04830137RecruitingEst. Dec 2026
NCT05131022RecruitingEst. Jan 2028
NCT07221500RecruitingEst. Oct 2030
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
Ofatumumab with GSK2110183Phase 21 trial
VAY736Phase 11 trial
Active Trials
NCT03400176Terminated39Est. Sep 2023
NCT01532700Completed28Est. Jun 2017
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
AcalabrutinibPhase 2Small Molecule
VenetoclaxPhase 22 trials
Active Trials
NCT03580928Active Not Recruiting72Est. Dec 2027
NCT03218683Terminated70Est. Oct 2021
Genentech
GenentechCA - Oceanside
1 program
1
ZanubrutinibPhase 2Small Molecule1 trial
Active Trials
NCT03824483Recruiting230Est. Feb 2026
BioCryst Pharmaceuticals
1 program
1
forodesine HClPhase 21 trial
Active Trials
NCT00640523Completed23Est. Nov 2011
Aptevo Therapeutics
2 programs
1
1
TRU-016 and bendamustinePhase 1/21 trial
TRU-016Phase 11 trial
Active Trials
NCT00614042CompletedEst. Mar 2012
NCT01188681CompletedEst. Dec 2014
Bristol Myers Squibb
2 programs
1
EGFRt/19-28z/4-1BBL CAR T cellsPhase 1Cell Therapy1 trial
Lisocabtagene maraleucelN/ACell Therapy5 trials
Active Trials
NCT06788652Recruiting300Est. Sep 2044
NCT06788639Recruiting300Est. Jun 2044
NCT06794268Recruiting300Est. Aug 2044
+3 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
IdelalisibPhase 1Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AbbVieObinutuzumab
Merck & Co.Dinaciclib
AbbVieAcalabrutinib
Nurix TherapeuticsNX-5948
AbbVieVenetoclax
GenentechZanubrutinib
Bristol Myers SquibbLisocabtagene maraleucel
AstraZenecaVenetoclax
AbbVieVenetoclax
NovartisOfatumumab with GSK2110183
Gilead SciencesIdelalisib
BioCryst Pharmaceuticalsforodesine HCl
Aptevo TherapeuticsTRU-016 and bendamustine
AbbVieObinutuzumab
Nurix TherapeuticsNX-5948

Showing 15 of 26 trials with date data

Clinical Trials (26)

Total enrollment: 2,111 patients across 26 trials

NCT03406156AbbVieObinutuzumab

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Start: Aug 2018Est. completion: Jul 2023120 patients
Phase 3Completed
NCT01580228Merck & Co.Dinaciclib

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

Start: Aug 2012Est. completion: Dec 201444 patients
Phase 3Completed
NCT07024706AbbVieAcalabrutinib

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Start: Jan 2026Est. completion: May 202980 patients
Phase 2Not Yet Recruiting
NCT07221500Nurix TherapeuticsNX-5948

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Start: Oct 2025Est. completion: Oct 2030
Phase 2Recruiting
NCT05105841AbbVieVenetoclax

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Start: Nov 2021Est. completion: Oct 202520 patients
Phase 2Completed
NCT03824483GenentechZanubrutinib

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Start: Feb 2019Est. completion: Feb 2026230 patients
Phase 2Recruiting
NCT03744676Bristol Myers SquibbLisocabtagene maraleucel

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Start: Nov 2018Est. completion: Sep 2023104 patients
Phase 2Completed
NCT03580928AstraZenecaVenetoclax

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Start: Aug 2018Est. completion: Dec 202772 patients
Phase 2Active Not Recruiting
NCT02966756AbbVieVenetoclax

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start: Oct 2017Est. completion: May 2029110 patients
Phase 2Recruiting
NCT01532700NovartisOfatumumab with GSK2110183

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Start: Feb 2012Est. completion: Jun 201728 patients
Phase 2Completed
NCT01203930Gilead SciencesIdelalisib

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Start: Oct 2010Est. completion: Jun 2016105 patients
Phase 2Terminated
NCT00640523BioCryst Pharmaceuticalsforodesine HCl

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Start: Mar 2008Est. completion: Nov 201123 patients
Phase 2Completed
NCT01188681Aptevo TherapeuticsTRU-016 and bendamustine

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Start: Sep 2010Est. completion: Dec 2014
Phase 1/2Completed
NCT06291220AbbVieObinutuzumab

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Start: Jan 2025Est. completion: Jul 20274 patients
Phase 1Active Not Recruiting
NCT05131022Nurix TherapeuticsNX-5948

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Start: Apr 2022Est. completion: Jan 2028
Phase 1Recruiting
NCT04830137Nurix TherapeuticsNX-2127

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Start: May 2021Est. completion: Dec 2026
Phase 1Recruiting
NCT03400176NovartisVAY736

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Start: Apr 2018Est. completion: Sep 202339 patients
Phase 1Terminated
NCT03218683AstraZenecaVenetoclax

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Start: Aug 2017Est. completion: Oct 202170 patients
Phase 1Terminated
NCT03085173Bristol Myers SquibbEGFRt/19-28z/4-1BBL CAR T cells

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Start: Mar 2017Est. completion: Mar 202639 patients
Phase 1Active Not Recruiting
NCT02538614Gilead SciencesIdelalisib

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Start: Dec 2015Est. completion: Jul 20172 patients
Phase 1Terminated
NCT00614042Aptevo TherapeuticsTRU-016

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Start: Jan 2008Est. completion: Mar 2012
Phase 1Completed
NCT06794268Bristol Myers SquibbLisocabtagene maraleucel

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Start: Feb 2025Est. completion: Aug 2044300 patients
N/ARecruiting
NCT06788652Bristol Myers SquibbLisocabtagene maraleucel

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Start: Feb 2025Est. completion: Sep 2044300 patients
N/ARecruiting
NCT06788639Bristol Myers SquibbLisocabtagene maraleucel

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Start: Feb 2025Est. completion: Jun 2044300 patients
N/ARecruiting
NCT06357754Bristol Myers SquibbLisocabtagene maraleucel

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Start: Oct 2023Est. completion: Oct 203850 patients
N/ARecruiting
NCT03873857AbbVieVenetoclax

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Start: Feb 2019Est. completion: Sep 202271 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
9m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
9m ago

Office Administrator

SystImmune
9m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
23m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
23m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
9 actively recruiting trials targeting 2,111 patients
11 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)